Quoin Pharmaceuticals announced the FDA's conditional approval of QYLEKI as the proposed brand name for QRX003, their investigational treatment for Netherton Syndrome, a rare skin disorder with no current approved therapies. QRX003 holds Orphan Drug Designations in the US, EU, and Japan, plus Fast Track and Rare Pediatric Disease status from the FDA. Quoin plans to start a pivotal Phase 3 trial in the second half of 2026 and aims for a New Drug Application filing in 2027. If approved, QYLEKI could become the first FDA-approved treatment for Netherton Syndrome, addressing a significant unmet medical need.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
